약학회지

ISSN 0377-9556 (PRINT)
ISSN 2383-9457 (ONLINE)

Table. 1.

Table. 1.

Study characteristics

EMPA-REG OUTCOME6) EMEPEROR-Reduced7) EMEPEROR-Preserved8) EMPULSE34)
Published year 2015 2020 2021 2022
Type of heart failure studied HFrEF HFrEF HFpEF Acute heart failure
Study design Randomized, double-blind, placebo-controlled trial Randomized, double-blind, parallel-group, placebocontrolled, event-driven trial Randomized, double-blind, parallel-group, placebocontrolled, event-driven trial Randomized, double-blind, placebo-controlled trial
Study drugs Empagliflozin 10 or 25 mg vs. placebo Empagliflozin 10 mg vs. placebo Empagliflozin 10 mg vs. placebo Empagliflozin 10 mg vs. placebo
Follow-up 3.1 years 16 months 26.2 months -
Inclusion criteria • Adults≥18 years of age with type 2 diabetes
• BMI≤45 kg/m2
• eGFR≥30 mL/min/1.73 m2
• Established CVD
• No glucose lowering agent use for at least 12 weeks before randomization and HbA1c≥7%, but <9%, or had received glucose lowering agent for at least 12 weeks before randomization and HbA1c≥7%, but <10%
Adults≥18 years of age with chronic HF (functional class II, III, or IV) with LVEF≤40% Adults≥18 years of age with chronic HF (functional class II, III, or IV) with LVEF≥40% Adults≥18 years of age with acute de novo or decompenstated chronic HF

BMI: body mass index; CVD: cardiovascular disease; eGFR: estimated glomerular filtration rate; HbA1c: hemoglobin A1c; HF: heart failure; HFrEF: heart failure with reduced ejection fraction; HfpEF: heart failure with preserved ejection fraction; LVEF: left ventricular ejection fraction

Yakhak Hoeji 2022;66:175-83 https://doi.org/10.17480/psk.2022.66.4.175
© 2022 Yakhak Hoeji